



*IPW*

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of: Katia Vancompennolle**

**Serial No.: 10/630,451**

**Filed: July 30, 2003**

**For: PHOSPHORYLATED GLYOXALASE  
I AND ITS USE**

**Confirmation No.: 5403**

**Examiner: C. Fronda**

**Group Art Unit: 1652**

**Attorney Docket No.: 2676-6045US**

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 5, 2006  
Date

Signature

Denise Dyer  
Name (Type/Print)

**COMMUNICATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**BEST AVAILABLE COPY**

Sir:

Enclosed is a copy of Priority Document 01200353.9 EP filed Jan. 31, 2001, for the above referenced application.

Respectfully submitted,

Allen C. Turner  
Registration No. 33,041  
Attorney for Applicant(s)  
TRASKBRITT  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: May 5, 2006  
ACT/dd

**THIS PAGE BLANK (USPTO)**



**Europäisches Patentamt**  
GD1

**European Patent Office**  
DG1

**Office européen des brevets**  
DG1

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr.**

**Patent application No.**

**Demande de brevet n°**

01200353.9 / EP01200353

The organization code and number of your priority application, to be used for filing abroad under the Paris Convention, is EP01200353

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R.C. van Dijk

**THIS PAGE BLANK (USPTO)**



Europäisches Patentamt  
GD1

European Patent Office  
DG1

Office européen des brevets  
DG1

Anmeldung Nr.:  
Application no.: 01200353.9  
Demande no:

Anmeldetag:  
Date of filing: 31.01.01  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Vlaams Interuniversitair Instituut voor  
Biotechnologie vzw.  
Rijvisschestraat 120  
9052 Zwijnaarde/BE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

**Phosphorylated glyoxalase I and its use**

In anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)  
Staat/Tag/Aktenzeichen / State/Date/File no. / Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation / International Patent Classification / Classification internationale de brevets:

C12N9/00

Am Anmeldetag benannte Vertragsstaaten / Contracting states designated at date of filing / Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

**THIS PAGE BLANK (USPTO)**

KVC/Glyox/079

**PHOSPHORYLATED GLYOXALASE I AND ITS USE**

The present invention relates to a phosphorylated form of mammalian glyoxalase I. The present invention relates further to the use of phosphorylated mammalian glyoxalase I to modulate methylglyoxal (MG)-modification of proteins (AGE formation) and consequent cell death, especially upon stress such as oxidative stress, or upon TNF treatment.

Tumor Necrosis Factor (TNF) is a pleiotropic cytokine, originally described for its ability to cause hemorrhagic necrosis of certain tumors *in vivo* (Carswell et al., 1975). In addition to its anti-tumor and anti-malignant cell effects, TNF has been reported to influence mitogenesis, differentiation and immunoregulation of various cell types.

The activities of TNF are mediated through two cell-surface receptors, namely TNF-R55 (CD120a) and TNF-R75 (CD120b), which are expressed by most cell types. TNF's effects are mediated primarily through TNF-R55. Upon activation of the receptor, adaptor proteins such as TRADD and TRAF are recruited and bind to the intracellular part of the clustered receptor (for review, see Wallach et al., 1999). These receptor-associated molecules that initiate signaling events are largely specific to the TNF/nerve growth factor receptor family. However, the downstream signaling molecules are not unique to the TNF system, but also mediate effects of other inducers. Downstream signaling molecules in the TNF system identified so far include: caspases, phospholipases, the three mitogen-activated protein (MAP) kinases, and the NF- $\kappa$ B activation cascade.

TNF-induced cell death in L929 cells is characterized by a necrosis-like phenotype and does not involve DNA fragmentation (reviewed by Fiers et al., 1999). It is independent of caspase activation and cytochrome c release, but is dependent on mitochondria and is accompanied by increased production of reactive oxygen intermediates (ROI) in the mitochondria that are essential to the death process (Goossens et al., 1995; Goossens et al., 1999). The latter was demonstrated by the fact that lipophylic anti-oxidantia when added 3h after TNF treatment could not only arrest the ongoing increased ROI production but could also arrest cell death (Goossens et al., 1995). Furthermore, the mitochondria translocate from a dispersed distribution to a perinuclear cluster (De Vos et al., 2000); functional implications of this mitochondrial translocation remain unclear.

+32 9 2446610

KVC/Glyox/079

While much effort has been directed at the molecular mechanism of the caspase-dependent cell death pathway, relatively little is known about the TNF-induced ROI-dependent cell death pathway. To identify molecules involved in the latter, we performed a comparative study of the phosphoproteins from TNF-treated and control cells by two-dimensional (2-D) gel electrophoresis. It is known that upon activation of the TNF receptor, several kinases/phosphatases are activated (Guy et al., 1992; Guy et al., 1991). However, most of the changes in phosphorylation occur very rapidly (2-15 min) upon binding of TNF to its receptors and most of them are transient and related to the gene-inductive activities of TNF.

To identify molecules that are involved in the cytotoxic process downstream of the receptor-proximal events, lysates from cells that had been stimulated with TNF for 1.5h are studied. Previously, oncoprotein 18 (Op18, stathmin) has been identified as a protein with reproducible and large increases in phosphorylation upon TNF-treatment. Op18 is responsible for TNF-induced microtubule stabilization that promotes cell death (Vancompernelle et al., 2000). Unexpectedly, we were able to demonstrate that glyoxalase I is also phosphorylated upon TNF treatment. Phosphorylated mammalian glyoxalase I has not yet been described.

Glyoxalase I, together with glyoxalase II, constitutes the glyoxalase system that is an integral component of the cellular metabolism of  $\alpha$ -ketoaldehydes and is responsible for the detoxification of the latter. The prime physiological substrate of the glyoxalase system is methylglyoxal (MG), which is cytotoxic. The major source of intracellular MG is the glycolysis namely, non-enzymatic and enzymatic elimination of phosphate from dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. The glyoxalase system, using glutathione (GSH) as cofactor, catalyzes the conversion of methylglyoxal to D-lactate in two consecutive steps (Racker, 1951). Glyoxalase I catalyses the isomerization of the hemithioacetal, produced by the nonenzymatic conjugation of methylglyoxal with glutathione (GSH), to S-D-lactoylglutathione which is then hydrolysed by glyoxalase II to D-lactate and GSH. D-lactate is then further metabolized to pyruvate by 2-hydroxy-acid dehydrogenase localized in the mitochondria. In addition to its role as detoxification system, it has been suggested that glyoxalase I, together with its substrate



+32 9 2446610

KVC/Glyox/079

MG, is involved in the regulation of cellular growth (for a review see Kalapos, 1999), but until now this role has not been found. Increased expression of glyoxalase I occurs in diabetic patients and in some types of tumor such as colon carcinoma (Ranganathan et al., 1993) and prostate cancer (Davidson et al., 1999). Also hypoxia can lead to increased expression of glyoxalase I (Principato et al., 1990). Recently, it has been shown that glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis (Sakamoto et al., 2000).

It is a first aspect of the invention to provide phosphorylated mammalian glyoxalase. The phosphorylation may be a single or a multiple phosphorylation. A preferred embodiment is a phosphorylated mammalian glyoxalase I comprising SEQ ID N° 1. Preferably, phosphorylation is carried out at position Ser 8 and/or Ser 21 and/or Ser 26 and/or Thr 107.

Another aspect of the invention is the use of a phosphorylated glyoxalase I to modulate MG-modification of proteins. Said phosphorylated glyoxalase I may be any glyoxalase I, known to the person skilled in the art, such as a fungal glyoxalase I or a plant glyoxalase I. Preferably, said glyoxalase I is a mammalian glyoxalase I. MG-modified proteins or advanced glycation end products (AGEs) are known to be synthesized in response upon a number of pathophysiological conditions *in vivo*, such as cataract formation (Shamsi 2000), vascular complications associated with chronic diabetes (Shinohara et al., 1998), tissue damage after ischemia/reperfusion (Oya et al., 1999) and aging (Corman et al., 1998). The term AGE, as used here, is used for any MG-modification of a protein, irrespective the way it is formed; the term MG-modification of proteins is considered as being equivalent with the term AGE formation.

Still another aspect of the invention is the use of phosphorylated glyoxalase I, or an inhibitor of the phosphorylation of glyoxalase I, preferably mammalian glyoxalase I to modulate TNF induced cell death. Said inhibitor can be any inhibitor that inhibits the phosphorylation of glyoxalase I; preferably said inhibitor is an inhibitor of the PKA activity.

A further aspect of the invention is the use of phosphorylated glyoxalase I, or an inhibitor of the phosphorylation of glyoxalase I to modulate stress induced cell death. Preferably, said stress is oxidative stress. Oxidative stress, followed by ROI induction and AGE

KVC/Glyox/079

formation is known to occur in several organisms, including plants, yeast, fungi and mammals. A preferred embodiment is the use of mammalian phosphorylated glyoxalase I to modulate oxidative stress induced cell death.

- 5 Still another aspect of the invention is the use of PKA to phosphorylate glyoxalase I. By modulating the phosphorylation of glyoxalase I, TNF induced cell death and stress induced cell death, preferably oxidative stress, can be modulated.

### BRIEF DESCRIPTION OF THE FIGURES

- 10 **Figure 1:** phosphorylation of glyoxalase I in control cells (left panel) and after 1.5 h of TNF treatment (right panel).

- Figure 2:** effect of the glyoxalase I inhibitor S-p-bromobenzylglutathione diester on TNF-induced cytotoxicity in L929s cells, in function of the incubation time. TNF is added at a concentration of 1000 units/ml; the inhibitor is added 1h10min prior to TNF at a concentration of 10  $\mu$ M (GI10) or 20  $\mu$ M (GI20). The time scale is calculated from the moment of TNF addition

- 15 **Figure 3:** western blots, developed with anti-human glyoxalase I polyclonal antibody, of 2-dimensional gels (pH 3-10) from total cell lysates derived from control cells (C), glyoxalase I inhibitor S-p-bromobenzylglutathione diester (20  $\mu$ M)-treated cells (I), TNF treated cells (TNF) and cells treated with TNF and glyoxalase I inhibitor (TNF + I), cells treated with the PKA inhibitor H89 (5  $\mu$ M) (H89) and cells treated with TNF and H89 (TNF + H89).

- 20 **Figure 4:** effect of different concentrations exogeneously added methylglyoxal on TNF-induced cell death. Measurement after 5,5 h of incubation with TNF and methylglyoxal at a concentration as indicated.

- 25 **Figure 5:** effect of different concentrations of the AGE formation inhibitor, aminoguanidine, on the TNF-induced cell death. Measurement after 16h of incubation with TNF and aminoguanidine at a concentration as indicated.

- Figure 6:** inhibition of TNF induced cell death by the PKA inhibitor H89 (2 h pre-treatment), in function of the incubation time. The concentration of the inhibitor H89 is as indicated on the graph. The time scale is calculated from the moment of the TNF addition.

+32 9 2446610

KVC/Glyox/079

## EXAMPLES

### *Materials and methods to the examples*

#### Cell lines and cultures

5 All L929 cells were cultured in Dulbecco's modified Eagle's medium supplemented with heat-inactivated fetal calf serum (5% v/v), heat-inactivated newborn calf serum (5% v/v), penicillin (100 units/ml), streptomycin (0.1 mg/ml), and L-glutamine (2mM), at 37°C in a humidified incubator under a 5% CO<sub>2</sub> atmosphere.

#### Reagents

10 Murine TNF (mTNF) was produced in *E. coli* and purified to at least 99% homogeneity in our laboratory. It had a specific activity of  $1.9 \times 10^8$  IU/mg of protein (National Institute for Biological Standards and Control, Potters Bar, UK), contained 4ng of endotoxin/mg protein, and was used at 1000 IU/ml. Propidium iodide (PI) and cycloheximide (CHX) (all from Sigma) were used at concentrations of 30  $\mu$ M and 50  $\mu$ g/ml, respectively.

#### Measurement of TNF-induced cell death by flow cytometry

15 Cell death in L929 was induced by addition of TNF to the cell suspension. Cell death was measured by quantifying PI-positive cells by FACS (FACSCalibur, Becton Dickinson, San Jose, CA). The PI dye was excited with an argon-ion laser at 488nm; PI fluorescence was measured above 590nm using a long-pass filter. Routinely, 3,000 cells were analyzed. Cell death is expressed as the percentage of PI-positive cells in the total  
20 cell population.

#### Radiolabeling of cells and preparation of the sub-cellular protein fractions

L929 cells were plated 48h prior to the experiment. <sup>32</sup>P labeling was carried out as described in (Guy et al., 1992). TNF treatments (1000 IU/ml, 1.5h) were done in the presence of cycloheximide (CHX), to synchronize cell death. To simplify the 2-D  
25 phosphoprotein pattern and subsequent computer-assisted analysis, we prepared two subcellular protein fractions. The cytosolic protein fraction, containing soluble cytoplasmic molecules and molecules derived from single-membrane organelles, was

+32 9 2446610

KVC/Glyox/079

obtained as the supernatant from digitonin (0.03%)-permeabilised cells. After rinsing once with excess PBS buffer, the remaining cell fraction was lysed in a CHAPS (2%)-containing buffer as described in (Guy et al., 1992). This lysate was then centrifuged (20,000g) and the supernatant was used as the organelle fraction; it is enriched for mitochondrial and cytoskeleton-derived proteins.

#### Two-dimensional (2D) gel electrophoresis

*Isoelectric focusing.* Isoelectric focusing was carried out on 18 cm IPG strips, pH 4-7 or pH 3-10 (Amersham Pharmacia Biotech), according to the manufacturer's instructions. Protein samples were precipitated with ethanol and redissolved in lysis buffer.

*SDS-PAGE.* The second dimension (SDS-PAGE) was run on large vertical gels (12.5 % acrylamide, Biorad).

#### Western blotting

Proteins were separated by SDS-PAGE (12.5 %) and transferred to a PVDF membrane (Hybond-P, Amersham Pharmacia Biotech). The blots were incubated with an anti-human glyoxalase I antibody, followed by ECL-based detection (Amersham Pharmacia Biotech).

#### Amino acid sequence analysis by MALDI-mass spectrometry

Following in-gel digestion of the excised protein with endoproteinase Lys-C (sequencing grade; Boehringer, Mannheim, Germany), a 10% aliquot of the generated peptide mixture was purified and concentrated on Poros® 50 R2 beads (Gevaert et al., 1998; Gevaert et al., 1997) and used for MALDI-MS peptide mass fingerprint analysis. However, partly due to contamination with human keratin peptides, the obtained peptide mass map did not lead to any unambiguous protein identification in a non-redundant protein database. Therefore the remainder of the peptide mixture was separated by RP-HPLC, a total of 20 fractions containing eluting peptides were obtained, which were all analysed by MALDI-MS. Adequate peptide ions were further selected for post-source decay (PSD) analysis (Spengler et al., 1992). A PSD-spectrum obtained from a peptide ion with a mass of 902.42 Da (measured in linear mode) present in the first RP-HPLC

+32 9 2446610

KVC/Glyox/079

fraction, could be unambiguously assigned to the peptide NH<sub>2</sub>-SLDFYTR-COOH present in human glyoxalase I (database entry number 417246) using the SEQUEST algorithm and a non-redundant protein database. Following a search in an EST-database the same peptide sequence was identified in many different mouse EST-clones. The identified peptide contains an arginine residue at its C-terminus instead of a lysine; an observation which we made several times when endoproteinase Lys-C was used as the protease.

In order to confirm our initial finding, PSD-analysis was conducted on a peptide with an apparent mass of 1396.53 Da present in RP-HPLC fraction 11. Based on the partially <sup>18</sup>O-labelled y-type fragment ions, a peptide sequence tag (391.24)YAI/LF(885.67) could easily be obtained. Furthermore a SEQUEST-search in a non-redundant protein database lead to the identification of the peptide NH<sub>2</sub>-FSLYFLAYEDK-COOH also belonging to human glyoxalase I. Again the same peptide sequence was found in different mouse EST-clones using the PSD-data and a SEQUEST-search in an EST-database. Based upon the amino acid sequence of human glyoxalase I, masses of peptide ions observed in the different RP-HPLC fractions could be assigned to the identified protein. Hereby, a total of 38% of the amino acid sequence of the protein was covered, again confirming the identification of glyoxalase I.

#### Assay of glyoxalase I activity

The glyoxalase I assay was performed according to a spectrophotometric method monitoring the increase in absorbance at 240 nm due to the formation of S-D-lactoylglutathione for 4 min at 20°C. The standard assay mixture contained 2 mM MG and 2 mM GSH in a sodium phosphate buffer (50 mM, pH 6.6). Before initiating the reaction by adding the total cytosolic protein fraction to the assay mixture, the mixture was allowed to stand for 10 min to ensure the equilibration of hemithioacetal formation.

#### D-Lactate measurements

D-Lactate measurements were performed by a fluorimetric assay using an endpoint enzymatic assay with D-lactate dehydrogenase (McLellan et al. 1992).

KVC/Glyox/079

Intracellular methylglyoxal measurements

Intracellular free methylglyoxal is detected as the 2-methylquinoxaline (2-MQ) derivative of methylglyoxal formed with o-phenylenediamine (o-PD) using the general approach of (Chaplen et al., 1996). Samples arrived frozen on dry ice and were stored at 20 °C until assayed. Samples were thawed at room temperature and maintained on ice during the assay procedure. Sample volume was increased to 2.5 ml with MilliQ water and the samples were sonicated (5 s, 30 W). 5 M HClO<sub>4</sub> (PCA; 0.25 ml) was added to precipitate macromolecules and the resulting mixture was incubated on ice for 20 min. Samples were then centrifuged (12,000xg, 10 min) to remove precipitated materials. The supernatant was passed through a C-18 SPE cartridge (Waters Sep-Pak tC18 plus cartridge, Millipore Corp, Marlborough, MA) that had been prepared by flushing with 6-8 ml of acetonitrile followed by 6-8 ml of 10 mM KH<sub>2</sub>PO<sub>4</sub> (pH 2.5, adjusted with concentrated H<sub>3</sub>PO<sub>4</sub>). The pre-derivatization SPE step removes phenol red and other interfering compounds. Samples were supplemented with 12.5 nmol 5-methylquinoxaline (5-MQ; internal standard) and 250 nmol o-PD (derivatizing agent) and reacted at 20 °C for 3.5 to 4 h.

*Sample Concentration*

All samples are concentrated after derivatization. For concentration, the samples are passed through a C-18 SPE cartridge, prepared as described above, at a rate of 1-2 ml/min. The cartridges are then rinsed with 1-2 ml 10 mM KH<sub>2</sub>PO<sub>4</sub> (pH 2.5) and the retentate eluted with 2 ml of acetonitrile. Eluates were evaporated to a volume of 200 µl using a Savant Speed-Vac Concentrator vacuum centrifugation unit (Savant Instruments, Farmingdale, NY) and filtered through 0.2-µm Gelman PVDF filters (Fisher Scientific, Chicago, IL) into sample vials.

*HPLC of Quinoxalines*

HPLC was performed as described previously (Chaplen et al., 1996) but with a mobile phase consisting of 35% acetonitrile/0.1% trifluoroacetic acid, pH 2.4 and 65% 10 mM phosphate/0.1% trifluoroacetic acid in HPLC grade water, pH 2.4. Under these modified conditions, 2-MQ eluted after 7.5 min and 5-MQ eluted after 11.2 min.

KVC/Glyox/079

**Example 1: TNF induces increased phosphorylation of Glyoxalase I**

Fig. 1 shows the autoradiogram of the two-dimensional gels from TNF-treated and control samples that were derived from cells labeled with  $^{32}\text{P}$ -orthophosphate. The protein spot with increased phosphorylation identified as glyoxalase I is indicated by an arrow. It was identified by mass spectrometry analysis of a peptide mixture derived from an in-gel digestion of the excised protein spot. The increased phosphorylation of glyoxalase I is already observed after 15 min of TNF treatment, but is much more pronounced after 1.5h of TNF treatment (Fig. 1). This indicates that the TNF-induced phosphorylation of GLO1 is an early but lasting event. Phosphorylation of mammalian glyoxalase I has not yet been described, but the sequence does contain several potential phosphorylation sites (Ranganathan et al., 1993). Interestingly, phosphorylation of yeast GLO1 has been observed during the sexual response of *S. cerevisiae* – specifically, during the arrest of cell division at the G1 phase, which occurs when haploid cells of one sex are exposed to the mating factor of the opposite type of cells (Inoue et al., 1990).

**Example 2: The Glyoxalase I inhibitor S-p-bromobenzylglutathione diethylester inhibits TNF-induced cell death**

To examine the role of glyoxalase I in TNF-induced cell death, we tested the effect of the cell permeable competitive inhibitor of glyoxalase I S-p-bromobenzylglutathione diester on cell death. Preincubation (1h10min) of L929 cells with this inhibitor strongly inhibits TNF-induced cell death in a concentration dependent manner (Fig. 2). An inhibition of 60% was obtained at a concentration of 20  $\mu\text{M}$  of the inhibitor. However, when the inhibitor and TNF were added at the same time, a synergistic effect on TNF-induced cell death was obtained (50% increase in cell death at a concentration of 20  $\mu\text{M}$  of the inhibitor). This synergistic effect is more pronounced at lower doses of TNF; that is, when the cells die more slowly.

KVC/Glyox/079

**Example 3: The Glyoxalase I inhibitor S-p-bromobenzylglutathione diethylester inhibits the TNF-induced phosphorylation of glyoxalase I**

5 This differential effect of the inhibitor on TNF-induced cell death prompted us to investigate whether the binding of the inhibitor to GLO1 competes and thus inhibits the TNF-induced phosphorylation of GLO1. Fig.3 shows the Western blots, developed with an anti-human glyoxalase I polyclonal antibody, of 2-dimensional gels (pH 3-10) from total cell lysates derived from TNF-treated and control cells and from TNF-treated and control cells that were first preincubated with the glyoxalase I inhibitor for 1h10min. In 10 the upper panels, one can see that TNF induces a more acidic phosphoisoform of glyoxalase I which is not well separated from the non-phosphorylated form (fills the space between the most left isoform and the main non-phosphorylated form. In the lower panels, one can see that in the presence of the glyoxalase I inhibitor TNF cannot induce the more acidic phosphoisoform of glyoxalase I (identical 2-D patterns as in the 15 control). These data show that the competitive inhibitor of glyoxalase I S-p-bromobenzylglutathione inhibits the TNF-induced phosphorylation of GLO1 and that phosphorylated glyoxalase I is essential for cell death. These data also suggest that phosphorylation of glyoxalase I modulates the active site of the enzyme.

20 Thus, the differential effect of the GLO1 inhibitor on TNF-induced cell death can be explained as follows:

- when the cells are pre-treated with the inhibitor, the inhibitor is already bound to GLO1 and thus hinders the TNF-induced phosphorylation of GLO1 which then leads to inhibition of phosphorylated GLO1-mediated MG-modification of proteins and 25 consequent cell death.
- however, when the cells are treated with the inhibitor and TNF together, the TNF-induced phosphorylation of GLO1 occurs first (via a receptor-activated kinase cascade) and the inhibitor can only bind to non-phosphorylated GLO1 (and not to phosphorylated GLO1) leading to inhibition of GLO1 and thus to accumulation of MG, resulting in 30 phosphorylated GLO1-mediated MG-modification of proteins and consequent cell death.



+32 9 2446610

KVC/Glyox/079

***Example 4: TNF-induced phosphorylation of glyoxalase I does not inhibit methylglyoxal detoxification***

For many years,  $\alpha$ -ketoaldehydes, exemplified by methylglyoxal, have been known to be carcinostatic, but their direct use as anti-cancer drugs is prevented by their rapid detoxification *in vivo* by the glyoxalase system. Therefore, glyoxalase I inhibitors have been developed as potential anti-cancer agents (Vince and Wadd, 1969) (Thornalley et al., 1996). Bearing this in mind, one would expect that TNF-induced phosphorylation of GLO1 would result in inhibition of the enzyme and thus in accumulation of MG with cytotoxicity as a consequence. However, our experiments with the GLO1 inhibitor do not support this expectation, because we would then expect a synergistic effect of the pre-incubated inhibitor on TNF-induced cell death. Indeed, measurements of GLO1 activity in lysates derived from TNF-treated and control cells showed no inhibition, but even a limited increase in GLO1 activity in TNF-treated cells. These experiments were repeated several times and each time gave the same results, with an average increase of 8% after 1h of TNF-treatment and 12% (from  $0,086 \pm 0,003$  to  $0,106 \pm 0,001$  units per  $8,5\mu\text{g}$  of total protein) after 1.5h of TNF-treatment. Measurement of the concentration of the end product of the glyoxalase system D-lactate showed an increase of 60% after 1.5h of TNF-treatment compared to control cells. This further confirmed that TNF did not inhibit GLO1 activity and that an increased flux of MG is converted through the glyoxalase system in TNF-treated cells.

***Example 5: TNF increases the intracellular concentrations of methylglyoxal***

As we consider it very unlikely that TNF would cause an increased detoxification of MG through the glyoxalase system, a more plausible explanation is that TNF induces an increase in the intracellular concentrations of MG via a pathway other than inhibition of glyoxalase I. An increase in the intracellular concentration of MG would then also automatically result in an increased flux of MG through the glyoxalase system and an increased GLO1 activity. Therefore, intracellular concentrations of MG were measured with a method that not only measures free MG, but also MG bound to biological molecules (majority of the MG), mainly proteins (Chaplen et al., 1998). Two independent

KVC/Glyox/079

experiments were performed in which intracellular concentrations of MG were measured in TNF-treated (1,5h) L929 cells compared to control cells. Each sample was measured in triplicate and each time gave very reproducible results. These results showed that TNF strongly increased the intracellular concentrations of MG, with an increase of 32% (from 0,91µMole in control cells to 1,20µMole in TNF-treated cells) in the one experiment and 94% (from 1,24µMole in control cells to 2,39µMole in TNF-treated cells) in the other experiment.

Also, exogenously added MG is strongly synergistic with TNF-induced cell death in a concentration dependent manner (Fig 4), while MG alone and used at the same concentrations is not cytotoxic for L929 cells. The synergistic effect of exogenously added MG is more pronounced at lower doses of TNF (100 U/ml) and also earlier in TNF treatment. This result can be explained by the fact that the TNF-induced increase of endogenous MG is more drastic at higher doses of TNF (1000U/ml) and later in TNF treatment.

#### ***Example 6: Inhibition of AGE formation inhibits TNF-induced cell death***

Increased endogenously produced levels of dicarbonyls, especially methylglyoxal, are involved in numerous pathogenic processes *in vivo*, including the formation of advanced glycation end-products (AGEs) which contribute to the pathophysiology of aging and to complications associated with chronic diabetes. They have been detected in several pathophysiological conditions *in vivo*, such as cataract formation, vascular complications in diabetes, and tissue damage after ischemia/reperfusion. All these conditions are characterized by increased oxidative stress, and recently it was shown that mitochondrial ROS are the direct cause of increased concentrations of MG and thus AGEs formation in diabetic hyperglycaemia (Nishikawa et al., 2000). Since TNF-induced cell death in L929 cells is characterized by increased production of mitochondrial ROS (Goossens et al., 1995) (Goossens et al., 1999) which are essential for cell death and increased levels of MG, we tested whether irreversible protein modification by MG plays a role in TNF-induced cell death. For this we used aminoguanidine, a nucleophilic hydrazine compound and inhibitor of AGE formation *in vivo* (Brownlee et al., 1986). The

+32 9 2446610

KVC/Glyox/079

percentage of cell death in L929 cells after 16h of TNF treatment (20 U/ml) with and without aminoguanidine is shown in Fig. 5. A maximum inhibition of cell death of 25% was obtained in the presence of 600 or 800  $\mu$ M of aminoguanidine and 15% inhibition in the presence of 400 $\mu$ M. This inhibition was less pronounced (average of 15% to 20%) when the cells died more rapidly by giving higher doses of TNF (500-1000U/ml). This could be due to the fact that the reaction of aminoguanidine with MG and MG-modified proteins is rather slow and that the MG protein modifications that occur during TNF-induced cell death are more rapid at higher doses of TNF and could even be enzymatically catalysed. These data indicate that irreversible protein modification by methylglyoxal might play a role in TNF-induced cell death.

***Example 7: The PKA inhibitor inhibits TNF-induced cell death and TNF-induced phosphorylation of glyoxalase I***

As it has been already shown that PKA is activated by TNF (Zhang et al., 1988), we examined whether pretreatment (2h) of L929 cells with the PKA inhibitor H89 had an effect on TNF-induced cell death. As shown in Fig. 6, the PKA inhibitor inhibits TNF-induced cell death in a concentration-dependent fashion and to a similar extent as the glyoxalase I inhibitor. Even an inhibitory effect was already obtained at relatively low concentrations of the inhibitor (1  $\mu$ M), while at the highest concentration (5  $\mu$ M) an inhibition of more than 50% was obtained. These data thus indicate that PKA plays a role in TNF-induced cell death. Next, we examined whether PKA was also responsible for the TNF-induced phosphorylation of endogeneous glyoxalase I in L929 cells. As shown in Fig. 3, pretreatment of the cells with the PKA inhibitor completely abolished the induction of the more acidic isoform by TNF. This suggests that the inhibitory effect of the PKA inhibitor on TNF-induced cell death could be largely due to the inhibition of phosphorylation of glyoxalase

KVC/Glyox/079

## REFERENCES

- Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., and Cerami, A. (1986). Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. *Science* 232, 1629-1632.
- 5 Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., and Williamson, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. *Proc. Natl. Acad. Sci. U. S. A* 72, 3666-3670.
- Chaplen, F.W., Fahl, W.E., and Cameron, D.C. (1998). Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. *Proc. Natl. Acad. Sci. U. S. A* 95,
- 10 5533-5538.
- Chaplen, F.W.R., Fahl, W.E., and Cameron, D.C. (1996). Method for determination of free intracellular and extracellular methylglyoxal in animal cells grown in culture. *Anal. Biochem.* 238, 171-178.
- Corman, B., Duriez, M., Poitevin, P., Heudes, D., Bruneval, P., Tedgui, A., and Levy, B.I. (1998). Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. *Proc. Natl. Acad. Sci. U. S. A* 95, 1301-1306.
- 15 Davidson, S.D., Cherry, J.P., Choudhury, M.S., Tazaki, H., Mallouh, C., and Konno, S. (1999). Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. *J. Urol.* 161, 690-691.
- 20 De Vos, K., Severin, F., Van Herreweghe, F., Vancompernelle, K., Goossens, V., Hyman, A., and Grooten, J. (2000). Tumor necrosis factor induces hyperphosphorylation of kinesin light chain and inhibits kinesin-mediated transport of mitochondria. *J. Cell Biol.* 149, 1207-1214.
- Fiers, W., Beyaert, R., Declercq, W., and Vandenabeele, P. (1999). More than one way to die: apoptosis, necrosis and reactive oxygen damage. *Oncogene* 18, 7719-7730.
- 25

KVC/Glyox/079

- Gevaert, K., Demol, H., Puype, M., Broekaert, D., De Boeck, S., Houthaeve, T., and Vandekerckhove, J. (1997). Peptides adsorbed on reverse-phase chromatographic beads as targets for femtomole sequencing by post-source decay matrix assisted laser desorption ionization-reflectron time of flight mass spectrometry (MALDI-RETOF-MS). *Electrophoresis* 18, 2950-2960.
- 5
- Gevaert, K., Demol, H., Sklyarova, T., Vandekerckhove, J., and Houthaeve, T. (1998). A peptide concentration and purification method for protein characterization in the subpicomole range using matrix assisted laser desorption/ionization-postsource decay (MALDI-PSD) sequencing. *Electrophoresis* 19, 909-917.
- 10
- Goossens, V., Grooten, J., De Vos, K., and Fiers, W. (1995). Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. *Proc. Natl. Acad. Sci. U. S. A* 92, 8115-8119.
- Goossens, V., De Vos, K., Vercammen, D., Steemans, M., Vancompernelle, K., Fiers, W., Vandenabeele, P., and Grooten, J. (1999). Redox regulation of TNF signaling. *Biofactors* 10, 145-156.
- 15
- Guy, G.R., Chua, S.P., Wong, N.S., Ng, S.B., and Tan, Y.H. (1991). Interleukin 1 and tumor necrosis factor activate common multiple protein kinases in human fibroblasts. *J. Biol. Chem.* 266, 14343-14352.
- Guy, G.R., Cao, X., Chua, S.P., and Tan, Y.H. (1992). Okadaic acid mimics multiple changes in early protein phosphorylation and gene expression induced by tumor necrosis factor or interleukin-1. *J. Biol. Chem.* 267, 1846-1852.
- 20
- Kalapos, M.P. (1999). On the promine/retine theory of cell division: now and then. *Biochem. Biophys. Acta* 1426, 1-16.
- McLellan, A.C., Phillips, S.A., Thornalley, P.J. (1992). Fluorometric assay of D-lactate. *Anal. Biochem.* 206 (1), 12-16.
- 25

KVC/Glyox/079

- Inoue, Y., Choi, B.Y., Murata, K., and Kimura, A. (1990). Sexual response of *Saccharomyces cerevisiae*: phosphorylation of yeast glyoxalase I by a cell extract of mating factor-treated cells. *J. Biochem. (Tokyo)* 108, 4-6.
- 5 Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.P., Giardino, I., and Brownlee, M. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* 404, 787-790.
- 10 Oya, T., Hattori, N., Mizuno, Y., Miyata, S., Maeda, S., Osawa, T., and Uchida, K. (1999). Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. *J. Biol. Chem.* 274, 18492-18502.
- Principato, G.B., Talesa, V., Norton, S.J., Contenti, S., Mangiabene, C., and Rosi, G. (1990). Induction of mouse liver glyoxalase I by hypobaric hypoxia. *Biochem. Int.* 20, 1019-1023.
- 15 Ranganathan, S., Walsh, E.S., Godwin, A.K., and Tew, K.D. (1993). Cloning and characterization of human colon glyoxalase-I. *J. Biol. Chem.* 268, 5661-5667.
- Sakamoto, H., Mashima, T., Kizaki, A., Dan, S., Hashimoto, Y., Naito, M., and Tsuruo, T. (2000). Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. *Blood* 95, 3214-3218.
- 20 Shamsi, F.A., Sharkey, E., Creighton, D. and Nagaraj, R.H. (2000). Maillard reactions in lens proteins: methylglyoxal-mediated modifications in the rat lens. *Exp Eye Res* 70, 369-380.
- 25 Shinohara, M., Thornalley, P.J., Giardino, I., Beisswenger, P., Thorpe, S.R., Onorato, J., and Brownlee, M. (1998). Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. *J. Clin. Invest* 101, 1142-1147.

+32 9 2446610

KVC/Glyox/079

Spengler, B., Kirsch, D., Kaufmann, R., and Jaeger, E. (1992). Peptide sequencing by matrix-assisted laser-desorption mass spectrometry. *Rapid Commun. Mass Spectrom.* 6, 105-108.

5 Thornalley, P.J., Edwards, L.G., Kang, Y., Wyatt, C., Davies, N., Ladan, M.J., and Double, J. (1996). Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. *Biochem. Pharmacol.* 51, 1365-1372.

10 Vancompernelle, K., Boonefaes, T., Mann, M., Fiers, W., and Grooten, J. (2000). Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death [In Process Citation]. *J. Biol. Chem.* 275, 33876-33882.

Vince, R. and Wadd, W.B. (1969). Glyoxalase inhibitors as potential anticancer agents. *Biochem. Biophys. Res. Commun.* 34, 593-598.

15 Wallach, D., Varfolomeev, E.E., Malinin, N.L., Goltsev, Y.V., Kovalenko, A.V., and Boldin, M.P. (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. *Annu. Rev. Immunol.* 17, 331-367.

Zhang, Y.H., Lin, J.X., Yip, Y.K., and Vilcek, J. (1988). Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6. *Proc. Natl. Acad. Sci. U. S. A* 85, 6802-6805.

20

+32 9 2446610

## SEQUENCE LISTING

&lt;110&gt; Vlaams Interuniversitair Instituut voor Biotechnolo

&lt;120&gt; PHOSPHORYLATED GLYOXALASE I AND ITS USE

&lt;130&gt; KVC/Glyox/079

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 1

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 184

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

<223> Lactoylglutathione lyase; Glyoxalase I: Accession  
Q04760

&lt;400&gt; 1

Met Ala Glu Pro Gln Pro Pro Ser Gly Gly Leu Thr Asp Glu Ala Ala  
1 5 10 15Leu Ser Cys Cys Ser Asp Ala Asp Pro Ser Thr Lys Asp Phe Leu Leu  
20 25 30Gln Gln Thr Met Leu Arg Val Lys Asp Pro Lys Lys Ser Leu Asp Phe  
35 40 45Tyr Thr Arg Val Leu Gly Met Thr Leu Ile Gln Lys Cys Asp Phe Pro  
50 55 60Ile Met Lys Phe Ser Leu Tyr Phe Leu Ala Tyr Glu Asp Lys Asn Asp  
65 70 75 80Ile Pro Lys Glu Lys Asp Glu Lys Ile Ala Trp Ala Leu Ser Arg Lys  
85 90 95Ala Thr Leu Glu Leu Thr His Asn Trp Gly Thr Glu Asp Asp Ala Thr  
100 105 110Gln Ser Tyr His Asn Gly Asn Ser Asp Pro Arg Gly Phe Gly His Ile  
115 120 125

1



+32 9 2446610

Gly Ile Ala Val Pro Asp Val Tyr Ser Ala Cys Lys Arg Phe Glu Glu  
130 135 140

Leu Gly Val Lys Phe Val Lys Lys Pro Asp Asp Gly Lys Met Lys Gly  
145 150 155 160

Leu Ala Phe Ile Gln Asp Pro Asp Gly Tyr Trp Ile Glu Ile Leu Asn  
165 170 175

Pro Asn Lys Met Ala Thr Leu Met  
180

KVC/Glyox/079

**CLAIMS**

1. A phosphorylated mammalian glyoxalase I.
2. The phosphorylated mammalian glyoxalase I according to claim 1, comprising SEQ  
5 ID N°1.
3. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation to modulate MG-modification of proteins.
4. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation to modulate TNF induced cell death.
- 10 5. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation to modulate cell death.
6. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation according to claim 5, whereby said stress is oxidative stress.
7. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation  
15 according to claim 3-6, whereby said phosphorylated glyoxalase I is a mammalian glyoxalase I.
8. The use of a phosphorylated glyoxalase I and/or an inhibitor of the phosphorylation according to claim 3-6, whereby said inhibitor is a PKA inhibitor.
9. The use of PKA to phosphorylate glyoxalase I.

20

+32 9 2446610

KVC/Glyox/079

**ABSTRACT**

The present invention relates to a phosphorylated form of mammalian glyoxalase I. The present invention relates further to the use of phosphorylated mammalian glyoxalase I to modulate MG-modification of proteins (AGE formation) and consequent cell death, especially upon stress such as oxidative stress, or upon TNF treatment.

10

1/5

Fig. 1






Fig. 3




2/5

Fig. 2



3/5

Fig. 4



4/5

Fig. 5





Fig. 6





**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**